Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Poor Prognosis0–1
- Intermediate-Poor Prognosis1.5–2
- Intermediate Prognosis2.5–3
- Good Prognosis3.5–4
The Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA) calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include age category. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates survival in patients with gastrointestinal cancers and brain metastases. Uses 4 prognostic factors to provide risk stratification and guide treatment decisions for patients with brain metastases from GI cancers.
Clinical Indication
The Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA) is indicated for bedside clinical practice to support Estimates survival in patients with gastrointestinal cancers and brain metastases. Uses 4 prognostic factors to provide risk stratification and guide treatment decisions for patients with brain metastases from GI cancers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Helps guide treatment selection and end-of-life decision-making.
GI-GPA Score = Age points (0-0.5) + KPS points (0-2) + Extracranial metastases points (0-0.5) + Number of brain metastases points (0-1)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age_category | string | Yes | Patient age category with different prognostic implications(years) |
| kps | string | Yes | Karnofsky Performance Status reflecting functional capacity |
| extracranial_metastases | string | Yes | Presence of extracranial metastases outside the brain |
| number_brain_metastases | string | Yes | Number of brain metastases identified on imaging |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Poor Prognosis | Worst survival group |
| 1.5–2 | Intermediate-Poor Prognosis | Below average survival |
| 2.5–3 | Intermediate Prognosis | Average survival |
| 3.5–4 | Good Prognosis | Best survival group |
Evidence-Based References (EBM)
- Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clin Transl Radiat Oncol. 2019;18:39-45. doi: 10.1016/j.ctro.2019.06.009.DOI: 10.1016/j.ctro.2019.06.009
- Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655-61. doi: 10.1016/j.ijrobp.2009.08.025.DOI: 10.1016/j.ijrobp.2009.08.025
- Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827-831. doi: 10.1001/jamaoncol.2016.3834.DOI: 10.1001/jamaoncol.2016.3834